The current (2017) European Leukemia Net (ELN) classification recommends the stratification of newly-diagnosed AML based on the mutational status of five genes NPM1, CEBPA, FLT3, ASXL1, TP53, and RUNX1 (2). This evidence concerns the gene TP53 and acute myeloid leukemia.